Enterprise Value

255.9M

Cash

151.7M

Avg Qtr Burn

-11.65M

Short % of Float

19.80%

Insider Ownership

2.02%

Institutional Own.

60.74%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Reproxalap Details
Dry eye syndrome

Big Mover™

Susp. Mover™

PDUFA

Approval decision

ADX-2191 (methotrexate injection (DHFR inhibitor)) Details
Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma, Retinitis Pigmentosa

NDA

FDA meeting

Reproxalap (ADX-102) Details
Rare diseases, Rare genetic disease, Allergic conjunctivitis

Phase 3

Update

ADX-629 Details
Sjögren-Larsson Syndrome

Phase 2

Data readout

ADX-629 Details
Chronic cough

Phase 2

Update

ADX-629 Details
Alcoholic hepatitis

Phase 2

Initiation

ADX-629 Details
Idiopathic Nephrotic Syndrome

Phase 2a

Data readout

ADX-629 Details
Atopic dermatitis

Phase 2a

Data readout